Mounjaro (generic name: tirzepatide) is a newer injectable medication approved for the treatment of type 2 diabetes and also used off-label for weight management. It stands out because it is a dual GIP and GLP-1 receptor agonist—meaning it mimics the effects of two key gut hormones (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1). This dual action enhances insulin sensitivity, reduces appetite, and slows gastric emptying, leading to improved blood sugar control and significant weight loss. Mounjaro is typically administered as a once-weekly subcutaneous injection.

In clinical trials, Mounjaro has shown impressive results for both glycemic control and weight reduction, sometimes surpassing other GLP-1 medications like Ozempic and Wegovy. It is generally used in combination with lifestyle changes such as diet and exercise. Like other drugs in its class, Mounjaro can cause side effects including nausea, vomiting, and diarrhea, particularly when starting treatment or increasing the dose. Because of its dual mechanism, Mounjaro represents a promising advancement in the treatment of obesity and type 2 diabetes.